10 completed. 10 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 10 |
| Phase 2 | 1 | Completed 1 |
Follow dotinurad: new trials by email Literature Review of dotinurad trials Research Report on dotinurad
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia dotinurad, dotinurad + allopurinol, allopurinol - Gout, Hyperuricemia | Phase 1 / Phase 2 | Completed | Urica Therapeutics Inc. | 20 | 2023-10-04 | 2026-06-10 |
| A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants Dotinurad - Healthy Volunteers | Phase 1 | Completed | Eisai Co., Ltd. | 26 | 2022-07-01 | 2023-09-14 |
| Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types) FYU-981 - Hyperuricemia With or Without Gout | Phase 1 | Completed | Mochida Pharmaceutical Company, Ltd. | 26 | 2018-01-04 | 2018-09-24 |
| Clinical Pharmacology of FYU-981 (Final Formulation) FYU-981 - Healthy | Phase 1 | Completed | Mochida Pharmaceutical Company, Ltd. | 12 | 2017-11-06 | 2017-12-12 |
| Drug-drug Interaction Study of FYU-981 and Oxaprozin FYU-981, Oxaprozin - Healthy | Phase 1 | Completed | Mochida Pharmaceutical Company, Ltd. | 12 | 2017-11-02 | 2022-09-14 |
| Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency) FYU-981 - Hepatic Insufficiency, Healthy | Phase 1 | Completed | Mochida Pharmaceutical Company, Ltd. | 24 | 2017-10-06 | 2018-09-24 |
| Clinical Pharmacology of FYU-981 (Subjects With Renal Insufficiency) FYU-981, (Oral single dosing) - Renal Insufficiency, Healthy | Phase 1 | Completed | Fuji Yakuhin Co., Ltd. | 18 | 2015-01-01 | 2015-03-06 |
| Clinical Pharmacology of FYU-981 (Elder Subjects) FYU-981, (Oral single dosing) - Healthy | Phase 1 | Completed | Fuji Yakuhin Co., Ltd. | 24 | 2014-05-01 | 2015-01-26 |
| Repeated Dose Phase I Study of FYU-981 FYU-981, (Oral daily dosing for 7 days), Placebo, (Oral daily dosing for 7 days) - Healthy | Phase 1 | Completed | Fuji Yakuhin Co., Ltd. | 18 | 2013-09-01 | 2015-01-28 |
| Single Dose Phase I Study of FYU-981 FYU-981, (Oral single dosing), Placebo, (Oral single dosing) - Healthy | Phase 1 | Completed | Fuji Yakuhin Co., Ltd. | 54 | 2013-03-01 | 2015-01-28 |
Gout (1) · Hepatic Insufficiency (1) · Hyperuricemia (1) · Renal Insufficiency (1)
Fuji Yakuhin Co., Ltd. (4) · Mochida Pharmaceutical Company, Ltd. (4) · Eisai Co., Ltd. (1) · Urica Therapeutics Inc. (1)
Japan (8) · China (1) · United States (1)
Katsuaki Nagasawa (1) · Kazuki Furuno (1) · Nagasawa Katsuaki (1) · Shigeki Matsumoto (1)